Ovarian cancer, melanoma, pancreatic cancer, gastric cancer, etc.
Conditions
Interventions
Sponsors
The First Bethune Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 - 65 years; 2. Target expression >=1 + as determined by immunohistochemistry (IHC) in a laboratory accredited by the sponsor; 3. Pathological diagnosis is Digestive tract tumors; 4. Patients who are unable or unsuitable for surgery or who have recurrence after surgery; 5. According to RECIST 1.1 version or EORTC or PERCIST of the standard has at least one measles extracranial measurable lesion has not received radiotherapy; 6. Expected survival of >= 90 days; 7. The main organs function properly, that is, meet the following criteria: 1) The ECOG physical status score is 0-2; 2) Blood test should meet the following criteria: HB >= 90g/L (no blood transfusion within 14 days); ANC >= 1.5x10^9/L; PLT >= 80 x 10^9/L; 3) Biochemical tests should meet the following criteria: TBIL 50 ml / min (Cockcroft-Gault formula); 8. There was no hemorrhagic disease or coagulation dysfunction; 9. No allergy to the contrast agent; 10. Women of childbearing age must have a pregnancy test (serum or urine) within 7 days before enrollment and the result is negative and are willing to use appropriate methods of contraception either during the experiment and 8 weeks after the last dose of CART (subject to sterilization or menopause women who have been at least 2 years old can be considered as having no fertility); 11. Participants voluntarily joined the study, signed informed consent, compliance is good, with follow-up.
Exclusion criteria
Exclusion criteria: 1. Previous history of other malignant tumors; 2. T cell transduction efficiency 140 mmHg, diastolic > 90 mmHg), patients with grade I or higher myocardial ischemia or myocardial infarction, grade I and above arrhythmias Including QT interval >= 440ms) or complete cardiac function; 5. Long-term unhealed chest or other parts of the wound or fracture; 6. Those with a history of abuse of psychotropic substances who can not be abstinent or who have mental disorders; 7. Past and current patients with objective evidence of a history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia, severely impaired pulmonary function; 8. There are fungi, bacteria, viruses, or other infections that can not be controlled or require antimicrobial treatment. If there is a response to active therapy, a simple urinary tract infection and no complication of bacterial pharyngitis are allowed after consultation with the medical examiner; 9. For subjects with previously used chemotherapy, >= 2 hematologic toxicity or >= 3 non-hematologic toxicity at enrollment according to NCI-CTCAE 4.0 criteria; 10. Known history of HIV or Hepatitis B (HBsAg positive) or Hepatitis C virus (anti-HCV positive) infection is known; 11. There are any indwelling catheters or drains (eg, percutaneous nephrostomy tubes, indwelling Foley catheters, bile ducts, or pleural/peritoneal/pericardial catheters). Allow use of a dedicated central venous catheter; 12. Brain metastases; 13. There is a CNS history or disease, such as seizure disease, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving CNS; 14. There is a significant immunodeficiency; 15. Have a history of severe hypersensitivity reactions to the major therapeutic agents used in this study, including fludarabine, cyclophosphamide, mesna, and tocilizumab and anti-infectives against CRS during pretreatment; 16. There was a history of deep venous thrombosis or pulmonary embolism within the first 6 months of enrollment; 17. A history of autoimmune diseases (eg, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) that cause damage to the terminal organ or that require systemic immunosuppression / systemic disease modulation over the past two years; 18. With hemorrhagic disease or coagulation dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR);safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of Response;Incidence of Adverse Events;Serum cytokine levels; | — |
Countries
China
Contacts
Public ContactJiuwei Cui
The First Bethune Hospital of Jilin University
Outcome results
None listed